Redx Pharma PLC is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis.
The company aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation.